Avid Bioservices Inc (CDMO)

[biopharm]

Could have the late Dr. Andrew Parsa also been on the fast track to quickly learning re: PS Targeting ?

This becomes a little shocking. Now, Dr. Wolchok has been working with platforms from the late (both young..) Dr. Philip Thorpe / Dr. Andrew Parsa.

This video below is an EYE opener for some that have any doubts : listen closely around the 3:14 min mark - 10 min and combine all this with the sabotage against Peregrine Pharmaceuticals.

----------------------------------------

The Roles of Bioethics in Industry: Perspectives from an Insider -- Dr. Llew Keltner

----------------------------------------

Now wouldn't it be interesting if AstraZeneca had someone like Dr. Keltner on their side (now via Pelican..) .... hmmmmm, I would think the door opens for AstraZeneca + Pelican Therapeutics and imagine.... combo's with PS Targeting would scare the hell out of Big Pharma

--------------------------------------

Dr. Llew Keltner, MD, Ph.D.

Llew Keltner, M.D., Ph.D. has a 30 year career in the biopharmaceutica industry and in business development. He is Chief Executive Officer of EPISTAT, an international healthcare technology transfer, corporate risk management and healthcare strategy company that he founded in 1972. From 2011-2013, Dr. Keltner was the Chief Executive Officer of AgonOx, a biotech company developing OX40 agonists for use in cancer therapy. In 2010 and 2011, Llew was the President of Novici Biotech, a privately-held gene and protein optimization firm. From 2001-2010, Dr. Keltner was Chief Executive Officer and President of Light Sciences Oncology, a privately-held biotechnology company developing a late stage, light-activated therapy for hepatocellular cancer and other solid tumors. From 1997 to 2004, Dr. Keltner was Chief Executive Officer of Metastat, a development-stage biotech company focused on cancer metastasis.

Dr. Keltner holds positions on the boards of Raptor Pharmaceuticals, where he serves as Chairman (NASDAQ:RPTP), Infostat, BioQuiddity, Oregon Life Sciences, and Goodwell Technologies. He is a previous Director of Light Sciences Corporation, Vital Choice, Thesis Technologies, Oread Companies, and MannKind Corporation (NASDAQ:MNKD). Dr. Keltner serves on the Clinical Advisory Board of Heat Biologics and on the Scientific Advisory Board of Pelican Therapeutics. He has also been a scientific advisory board member at Lifetime Corporation, ASB Meditest, Oread Laboratories, Hall-Kimbrell, and aaiPharma. Dr. Keltner is an Associate Professor at Case Western Reserve School of Medicine, and a Guest Lecturer and Director in the Bioethics Program at Columbia University School of Medicine. He is currently a member of the American Society of Clinical Oncology, American Medical Association, International Association of Tumor Marker Oncology, American Association of Clinical Chemistry, and Drug Information Association. Dr. Keltner received an M.S. in Epidemiology and Biostatistics, a Ph.D. in Biomedical Informatics and an M.D. from Case Western Reserve University in Cleveland, Ohio. Dr. Keltner has also authored many research publications, and is a frequent speaker and panelist at industry conferences.

http://www.pelicantherapeutics.com/aboutus.php

-----------------------------

Until 2013, Dr. Keltner served as the Chief Executive of AgonOx, a private US biotech company working to develop OX40 agonists for use in cancer therapy. At AgonOx, he engineered a partnership with Medimmune LLC, the global biologics arm of Astra Zeneca PLC, to advance the private company's immune system activators. He served as the Chief Executive Officer of MetaStat from 1997 to 2004 and served as its Chairman. Dr. Keltner served as Chairman of Light Sciences Corporation. He served as Chairman of Light Sciences Oncology Inc. He serves as a Member of Scientific & Clinical Advisory Board at Heat Biologics, Inc. He served as a Director of ImmunoVaccine Inc. since January 20, 2014 until September 25, 2014. He served as a Director of Light Sciences Oncology Inc. since December 2004. He served as Chairman of the Board of Raptor Pharmaceuticals Corp. from July 2013 to August 1, 2015. He has been an Independent Director of Raptor Pharmaceuticals Corp. since September 2009. He serves a Director of Infostat Inc., Oregon Life Sciences, LKHealthnet Inc. and Goodwell Technologies Inc.

http://www.bloomberg.com/research/stocks/private/person.asp?personId=920759&privcapId=7828330

-----------------------------